Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Healthcare diagnostics catalyst with improving fundamentals: on 2026-08-05 Q2 revenue rose 45% YoY to $263.7M, full-year 2026 guidance was raised to $1.03B-$1.04B, and Caris Detect plus PTEN IHC testing expansion add product momentum.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Margin Recovery ⢠Strong Liquidity ⢠Net Losses CAI shows improving margins and positive EBIT with strong liquidity, but persistent net losses, high interest costs, rising leverage, cash outflows, and demanding valuation warrant caution.
Price Behavior
Key Price Behavior Insights: ⢠Modest uptrend ⢠Pullback underway ⢠Key breakout Support Level: $24.58â$24.80 Resistance Level: $25.63â$26.38 CAI is modestly bullish over the last month above its 21-day average, but holding $24.58â$24.80 support and breaking $25.63â$26.38 resistance are key after its pullback from $28.01.
Sentiment & News
Key News Insights: ⢠Raised guidance ⢠Break-even earnings ⢠AI expansion Caris Life Sciences delivered strong growth, improved profitability, and expanding AI/precision-oncology initiatives, supporting a positive outlook.
AI Summary
CAI's 45% growth, improving margins, and positive free cash flow make it a credible earnings-inflection story, but its premium valuation is justified only if operating profit consistently exceeds interest expense and converts into durable cash generation; investors should watch the next quarters for sustained FCF expansion rather than chase revenue growth alone.
Description
Caris Life Sciences is a US-based provider of molecular profiling services and related laboratory and data offerings to clinical and biopharmaceutical customers worldwide. The company supplies tissue- and blood-based tests for cancer treatment selection and supports drug development through laboratory execution, data products, and research services. Founded in 2008, Caris is headquartered in Irving, Texas.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Aug 6 | Aug 13 | CAI | Caris Life Sciences, Inc. | Healthcare diagnostics catalyst with improving fundamentals: on 2026-08-05 Q2 revenue rose 45% YoY to $263.7M, full-year 2026 guidance was raised to $1.03B-$1.04B, and Caris Detect plus PTEN IHC testing expansion add product momentum. | Closed | +10.9% |
| Jun 26 | Jul 3 | CAI | Caris Life Sciences, Inc. | CAI has favorable near-term momentum and business catalysts: Q1 revenue rose 79% YoY to $216.2M, recent updates include product launch activity, MolDX approval, New York authorization filing, clinical validation progress, expanded oncology network, a $100M buyback authorization, and about 17.8% stock gain over 21 trading days. | Closed | -1.1% |
| Jun 18 | Jun 25 | CAI | Caris Life Sciences, Inc. | Constructive momentum plus catalysts: Q1 2026 revenue grew 79% YoY to $216.2M with positive free cash flow, liquidity is strong, and recent supports include a $100M buyback authorization and MolDX approval for Caris ChromoSeq. | Closed | +1.3% |
| Jun 9 | Jun 16 | CAI | Caris Life Sciences, Inc. | Positive catalyst stack with Q1 2026 revenue of $216.2M, up 79% YoY, plus Caris MI Clarity launch, Caris ChromoSeq launch and MolDX approval, NY State authorization filing for Caris Assure, and a $100M share repurchase program announced on 2026-06-08. | Closed | +6.0% |